MEA Chlamydia Infection Diagnostics And Therapeutics Market

MEA Chlamydia Infection Diagnostics and Therapeutics Market Size (2023 to 2028)

The size of the Middle East and Africa Chlamydia Infection Diagnostics and Therapeutics market is forecasted to be growing at a CAGR of 5.3% during the forecast period. The market size is predicted to grow USD 0.10 billion by 2028 from USD 0.07 billion in 2023. It captures 3% of the global market share.

The chlamydia infection diagnostics and therapeutics market in the MEA are expected to be driven by the proliferation of Chlamydia infection across the region and the increasing number of treatments of sexually transmitted diseases. Also, the Growing demand for improved diagnostic tools for pelvic inflammatory illness and signs of chlamydial infection in women at risk of tubal injury is expected to propel the market growth. In addition, the market is more likely to witness significant growth due to the rising focus on treating sexually transmitted diseases across the region.

Chlamydia trachomatis is the most commonly reported sexually transmitted infection in the world. In addition, the rate of reported chlamydia infection diagnoses continues to increase the MEA regional chlamydia market growth.

In addition, increasing funding for research and development activities, growing awareness regarding STDs in emerging countries such as South Africa, Saudi Arabia, and UAE are increasing the market growth. 

The continuous rise in the number of diagnosed chlamydia cases is due to a preference shift toward more extensive diagnostic tests, and testing of asymptomatic people with greater sensitivity, which is a shift from culture-based methods to nucleic acid amplification tests (NAATs), is more likely to expand market growth during the forecast period.

Physicians' prescription preferences for antibiotics like macrolides and tetracycline are driving the market for chlamydia infection therapies. Therefore, the macrolide sector is expected to expand at a favorable rate over the forecast period. The direct fluorescent sub-segment follows, accounting for the MEA Chlamydia Infection diagnostics market's second-largest share.

In low and middle-income countries, lack of awareness about chlamydia diagnostic tests and the shame associated with volunteer chlamydia screening can hinder market expansion. In addition, those between the ages of 16 and 25, afraid of social embarrassment, are the most likely to get chlamydia, leading to untreated or undiagnosed infections.

This research report on the MEA Chlamydia Infection Diagnostics and Therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

• Diagnostics             
  • Nucleic Acid Amplification Tests (NAATs)
  • Direct Fluorescent Tests
  • PCR
• Therapeutics          
  • Macrolides
  • Quinolones
  • Sulfonamides
  • Tetracycline
  • Aminopenicillins

By End User:

• Diagnostics             
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
• Therapeutics          
  • Hospital Pharmacies
  • Drugstores
  • Retail Pharmacies
  • Online Pharmacies

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA Chlamydia Infection Diagnostics and Therapeutics Market is the least attractive market in the global market but estimated to account for a substantial share in the global market during the forecast period. The regional market growth is attributed to the higher spending in healthcare among the people, evolving healthcare infrastructure, and Technological advancements in the healthcare sector. Besides that, favorable reimbursement policies from public and private health insurance companies and a high level of awareness among young people in developed countries in the region such as South Africa and the United Arab Emirates are driving the market for chlamydia infection diagnostics and therapeutics. The major countries such as UAE, Saudi Arabia, and South Africa significantly contribute to the MEA regional market growth. Increased chlamydia infection rates among the population, proactive governmental and private sector awareness campaigns, and improved diagnosis and treatment rates have contributed to the region's leading position in the market. Also, the increasing investments by the government and private organizations are encouraging market growth in these countries. 

KEY MARKET PLAYERS:

A few prominent companies operating in the MEA MEA Chlamydia Infection Diagnostics and Therapeutics Market profiled in this report are Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.